Cadrenal (CVKD) CFO disposes 107 shares under 10b5-1 at $13.99

Q: What did CVKD CFO Matthew Szot report on the Form 4?

The CFO reported a sale of 107 shares of common stock at $13.99 per share on 10/06/2025, leaving 17,026 shares beneficially owned.

Q: Was the CVKD sale part of a prearranged trading plan?

Yes. The filing states the sale was made pursuant to a Rule 10b5-1 trading arrangement.

Q: Who signed the Form 4 for CVKD?

The Form 4 is signed by Matthew K. Szot on 10/07/2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cadrenal Therapeutics (CVKD) Chief Financial Officer Matthew K. Szot reported a sale of common stock under a prearranged trading plan. The Form 4 shows a disposition of 107 shares at $13.99 per share on 10/06/2025, leaving the reporting person with 17,026 shares beneficially owned. The filing indicates the sale was made pursuant to a Rule 10b5-1 arrangement and is signed by the reporting person.

Positive

Sale executed under a Rule 10b5-1 plan, which provides an affirmative defense for preplanned trades
Reporting person retains 17,026 shares, indicating continued meaningful ownership

Negative

Insider disposition of 107 shares reduces insider share count and may be viewed negatively by some investors

Insights

CFO sold a small number of shares under a 10b5-1 plan, leaving material ownership.

The reported transaction is a disposition of 107 common shares at $13.99 executed on 10/06/2025, and the filing explicitly states it was made under a Rule 10b5-1 trading arrangement. A 10b5-1 plan typically provides affirmative defense against insider trading accusations when properly adopted.

Key dependencies include the plan's effective dates and any blackout periods (not disclosed here). Monitor any future Form 4 filings for additional sales or changes in ownership to assess trend over the next several quarters.

Insider Trade Summary

Net Seller: 107 shares

Net Sell 1 txn

Insider Szot Matthew K

Role Chief Financial Officer

Sold 107 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock	107	$13.99	$1K

Holdings After Transaction: Common Stock — 17,026 shares (Direct)

Footnotes (1)

F1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement.

FAQ

What did CVKD CFO Matthew Szot report on the Form 4?

The CFO reported a sale of 107 shares of common stock at $13.99 per share on 10/06/2025, leaving 17,026 shares beneficially owned.

Was the CVKD sale part of a prearranged trading plan?

Yes. The filing states the sale was made pursuant to a Rule 10b5-1 trading arrangement.

Does the Form 4 indicate the sale was an amendment or part of multiple filers?

No. The Form 4 is filed by one reporting person and is not marked as an amendment.

Who signed the Form 4 for CVKD?

The Form 4 is signed by Matthew K. Szot on 10/07/2025.

How much beneficial ownership does the reporting person have after the sale?

After the reported disposition, the reporting person beneficially owns 17,026 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/07/2025 - 08:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Szot Matthew K

(Last)

(First)

(Middle)

C/O CADRENAL THERAPEUTICS, INC.

822, A1A NORTH, SUITE 306

(Street)

PONTE VEDRA

32082

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/06/2025		S		107	D	$13.99⁽¹⁾	17,026	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement.

	/s/ Matthew K. Szot	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR